Insight

Karl Semaan: First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma

Karl Semaan/X

Aug 16, 2024, 14:16

Karl Semaan: First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma

Karl Semaan, Postdoctoral Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“Just in European Urology, our study on first-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma.

Effort co-led with Talal El Zarif with amazing mentorship from Daniel Heng and Toni Choueiri.”

Source: Karl Semaan/X

Authors: Talal El Zarif, Karl Semaan, Wanling Xie, Marc Eid, Martin Zarba, Wadih Issa, Tian Zhang, Charles B. Nguyen, Ajjai Alva, Catherine C. Fahey, Kathryn E. Beckermann, Jose A. Karam, Matthew T. Campbell, Giuseppe Procopio, Marco Stellato, Sebastiano Buti, Anezka Zemankova, Bohuslav Melichar, Francesco Massari, Veronica Mollica, and Toni K. Choueiri.

adjuvant immunotherapy

adjuvant immunotherapy Ajjai Alva Anezka Zemankova Bohuslav Melichar cancer Catherine C. Fahey Charles B. Nguyen Daniel Heng european urology Francesco Massari Giuseppe Procopio Jose A. Karam Karl Semaan Kathryn E. Beckermann Marc Eid Marco Stellato Martin Zarba Matthew T Campbell OncoDaily Oncology renal cell carcinoma Sebastiano Buti Talal El Zarif Tian Zhang Toni Choueiri Toni K. Choueiri Veronica Mollica Wadih Issa Wanling Xie

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage